MANÜ Telehealth Review: What Its GLP-1 Documentation Establishes—and What It Does Not

A telehealth website can document what a company offers without proving how well its treatment works. That distinction matters with MANÜ Telehealth, which markets compounded injectable semaglutide and tirzepatide for weight loss. Its public pages describe an intake process, pharmacy fulfillment and ongoing support. They also contain conflicting statements about geographic coverage and clinical responsibilities. For a prospective patient, the central evidence question is not simply whether these medication names appear in research, but whether the advertised service and preparation are adequately documented.

This review examines public documentation consulted October 19, 2026, alongside FDA guidance and clinical research. It separates MANÜ’s commercial descriptions from evidence about medicines studied in trials. The documents establish a recognizable virtual-care offering, including named healthcare and technology entities, prescription-dependent access and subscription terms. They do not establish provider-specific weight-loss outcomes, independently verified clinician credentials or a complete GLP-1 payment schedule. Those gaps do not prove poor care, but they limit what a reader can confidently conclude before enrolling.

At a glance

Advertised GLP-1 preparations: MANÜ lists compounded injectable semaglutide and compounded injectable tirzepatide; these preparations are not FDA approved.
Sources: [6] [8] [1]
Healthcare and technology entities: The legal center identifies Ziggy Telehealth LLC as the practice shown as MANÜ Telehealth and Medoura, operated by CoFabri LLC, as the technology platform.
Sources: [10]
Unresolved geographic conflict: The homepage advertises coverage in all 50 states, while the privacy policy says services are available only to Florida residents.
Sources: [9] [12]
Incomplete advertised pricing: Separate homepage blocks advertise GLP-1s from $4/day and from $5/day, without establishing the product, supply quantity or full billing terms behind either figure.
Sources: [9]
Cancellation is not a refund promise: General subscription cancellation is requested by email and normally takes effect at the current cycle’s end; partial periods generally are not refunded.
Sources: [13]

Start with what the offering actually is

MANÜ’s weight-loss catalog identifies two relevant offerings: compounded semaglutide, injectable, and compounded tirzepatide, injectable. These are documented as compounded preparations, not as named FDA-approved branded products. The semaglutide page says preparation occurs through a licensed compounding pharmacy pursuant to a patient-specific prescription. The homepage also acknowledges that FDA has not evaluated its compounded GLP-1 medications for safety, quality or efficacy. That disclosure is more informative than the medication name alone.

The catalog extends beyond GLP-1 treatment. MIC Ultraburn is presented as an injectable combination of methionine, inositol and choline and marketed as an add-on to GLP-1 medications. Other listings include NAD+, sermorelin, glutathione and Bliss Tabs under longevity or sexual-health categories. These listings establish what MANÜ markets; they do not establish that the add-on improves GLP-1 outcomes. The consulted clinical context does not substantiate that provider-specific enhancement claim.

FDA approval applies to a particular drug product, not to a telehealth brand or pharmacy. FDA recommends compounded drugs for patients whose medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Nonapproval does not, by itself, prove clinical inequivalence. Our guide to approved medicines versus compounded preparations explains why product status and treatment evidence must be considered separately rather than collapsed into a simple endorsement or rejection.

Different documents answer different evidence questions
Documented item	What it supports	What it does not establish
Compounded injectable product pages	The advertised formulation category and route	Equivalence to a particular approved product
Published clinical trials	Outcomes in the studied populations and treatment arms	MANÜ-specific results
Named clinical team	The credentials MANÜ publicly presents	Independent licensing verification
Pharmacy and shipping statements	The advertised fulfillment arrangement	A guaranteed delivery date or verified cold chain
Daily starting prices	A partial advertising price	The complete charge for a treatment cycle

Sources: [6] [8] [11] [9] [1]

The clinical research is not a MANÜ performance report

STEP 1 studied 1,961 adults with obesity, or overweight plus a weight-related condition, without diabetes. Over 68 weeks, mean weight change was −14.9% with subcutaneous semaglutide 2.4 mg weekly versus −2.4% with placebo; both groups received lifestyle intervention. Those details identify the study, not a dosing recommendation. Gastrointestinal events caused discontinuation in 4.5% versus 0.8%, respectively, and Novo Nordisk funded the trial. The STEP 1 evidence guide explores those boundaries.

SURMOUNT-1 enrolled 2,539 adults with obesity, or overweight plus a weight-related complication, excluding diabetes, for 72 weeks. Mean weight changes with studied subcutaneous tirzepatide doses of 5, 10 and 15 mg weekly were −15.0%, −19.5% and −20.9%, respectively, versus −3.1% with placebo. Gastrointestinal events were most common. Adverse-event discontinuation rates were 4.3%, 7.1% and 6.2% in those dose groups and 2.6% with placebo. Eli Lilly funded the trial.

Neither trial tested MANÜ’s service or its compounded preparations. Their results cannot establish outcomes for its pharmacy products, optional blends or an individual patient. Nor does comparing the two studies produce a randomized head-to-head ranking. Our SURMOUNT-1 reading guide keeps the studied groups and limitations in view. The useful question for MANÜ is what evidence supports the specific preparation offered—not whether an ingredient name has appeared in a successful trial.

Sources: [3] [4]

Who is responsible for the clinical service?

The intake consent says the platform supplies technology only and healthcare services come from Ziggy Telehealth LLC. The legal center likewise identifies Ziggy as the healthcare practice shown to patients as MANÜ Telehealth. Separately, it identifies Medoura as a technology platform owned and operated by CoFabri LLC, explicitly stating that Medoura is not a healthcare provider, medical practice, pharmacy, laboratory or emergency service. These distinctions help identify responsibilities that branding alone can obscure.

The general terms create a complication: they say MANÜ Telehealth is not a licensed medical provider and does not practice medicine, with decisions assigned to independent licensed healthcare professionals. That language does not align neatly with the legal center’s practice identification. The team page lists Cristina, Nadja and Richard as nurse practitioners and Selvia as a family nurse practitioner, while a treatment page says an approved patient receives a prescription from a board-certified physician. A nurse practitioner is not necessarily a physician.

These discrepancies do not establish that the actual treating professional lacks appropriate credentials. They mean the public record does not clearly identify who will treat a particular patient or reconcile every description of the service. The consulted material does not provide surnames, license numbers or state assignments for the displayed team. Before payment, a useful request is the treating professional’s full name, credential, practice affiliation and role, together with clarification of which entity holds clinical responsibility.

Sources: [5] [10] [13] [7] [6]

Access depends on more than completing the questionnaire

The intake begins with an email address and phone number, allowing an applicant to start or resume the application. MANÜ advertises a free initial assessment taking less than five minutes, with nothing charged. That describes the questionnaire experience, not a promised clinical review time. The advertised process asks about health goals and medical history for review by healthcare professionals. No in-person visit is advertised as necessary, but the consulted documentation does not fully specify the consultation format.

The terms require users to be at least 18 and provide accurate, current and complete information. Both GLP-1 product pages describe adults with a BMI of at least 30, or at least 27 with weight-related conditions, as the intended population. These published thresholds are not a guarantee of eligibility or prescribing. The terms expressly say the provider-patient relationship begins only upon the professional’s explicit acceptance and that a prescription remains a clinical decision, not a guaranteed purchase outcome.

Geography is a more immediate unresolved issue. The homepage claims provider and pharmacy coverage in all 50 states, subject to change and confirmation through the applicant’s address. The privacy policy instead says services are unavailable outside Florida and instructs non-Florida residents not to use them. It also excludes people outside the United States and residents of other countries. Readers should not treat the nationwide advertisement as settled availability; a state-specific written explanation is needed to reconcile the conflict.

Sources: [5] [13] [6] [8] [9] [12]

Pharmacy fulfillment is documented more clearly than delivery timing

MANÜ states that it is not an internet pharmacy and does not dispense, ship or distribute medication from its own facility or website. Instead, it says prescribed medications are dispensed exclusively by a U.S. 503A pharmacy. Its privacy policy names Boudreaux, Shields Pharmacy and Hallandale as pharmacies that prepare and ship prescribed medication. Those are documented relationships or descriptions, not independent verification of pharmacy licensing or confirmation of which pharmacy would serve a particular order.

The advertised process promises direct-to-door delivery with free, discreet packaging from a U.S. pharmacy described as licensed. The consulted material does not establish clinical review, preparation, dispatch or arrival timelines. It also does not specify the cold-chain protocol or replacement process for a damaged clinical shipment. Free shipping is a stated package feature, not free treatment or a delivery guarantee. The assigned pharmacy and shipment contact are therefore practical details to obtain before fulfillment.

Temperature concerns deserve an explicit boundary: FDA advises not using an injectable GLP-1 drug that arrives warm or with insufficient refrigeration, and contacting the provider or dispensing pharmacy. FDA also reports measuring or administration errors with compounded medication, some involving hospitalization. These reports do not establish a MANÜ-specific event rate. Readers should obtain clear instructions from their prescriber or pharmacist rather than infer a dose from a review, vial photograph or another patient’s experience.

Sources: [9] [12] [1]

Daily advertising prices do not establish the actual bill

Two homepage blocks advertise different starting points: GLP-1s from $4/day and GLP-1s from $5/day, both alongside free shipping language. Neither block establishes which medicine, presentation, supply quantity or commitment produces that price. The difference is unresolved. These are partial starting-price advertisements, not established monthly charges, introductory offers or complete cycle quotes. Converting either into a monthly or annual total would create precision the documentation does not support.

The homepage FAQ says each medication package includes the online consultation, medication, supplies and shipping. That is useful, but it does not supply the missing semaglutide or tirzepatide package price or billing interval. MIC Ultraburn separately starts at $150, without a stated supply period or charge frequency in its plan block. The consulted pages also do not establish insurance acceptance, medication coverage, prior-authorization assistance or HSA/FSA payment availability; generic privacy references to insurers do not answer those questions.

Certain services use recurring billing, with the applicable fee and frequency stated at purchase. Subscription prices may change with advance notice, and continued use after the effective date constitutes acceptance under the terms. Promotional codes can have product restrictions, limited availability and expiration without notice. Before authorizing payment, request the actual first charge, renewal charge, interval, included preparation and supplies, and any separate laboratory costs. None should be inferred from a daily headline or the free assessment.

Sources: [9] [11] [13]

Follow-up claims need an operational explanation

The institutional page advertises regular follow-up consultations, progress tracking, treatment-plan adjustments and 24/7 patient support. Those are meaningful service claims, but the consulted documentation does not specify consultation frequency, response times or whether particular contacts involve the treating clinician. An always-available channel is not necessarily continuous clinical monitoring. A prospective patient should ask what follow-up is scheduled, how concerns reach a clinician and what happens when a refill decision requires additional assessment.

The legal center explicitly warns that messages, forms, intake submissions and refill requests may not be reviewed immediately. It says the platform is not for emergencies, directing emergencies to 911 or an emergency department and U.S. suicide, self-harm or mental-health crises to call or text 988. That limitation must be read alongside—not displaced by—the 24/7 support advertisement. Billing, refund, subscription, pharmacy and shipping questions are directed to the responsible practice, merchant or pharmacy identified in the workflow or receipt.

NIDDK describes follow-up as evaluation of response and tolerability, not merely continuation of payments. Medicine selection also involves health conditions, other medicines, family history, side effects and cost. MANÜ’s public pages do not fully define required laboratory testing, associated costs or requirements for people already using GLP-1 medication. Our guide to clinical follow-up beyond renewals provides a useful framework for asking how those responsibilities are handled, without treating public marketing as a complete care protocol.

Sources: [7] [10] [2]

Cancellation and records have separate rules

For general subscriptions, MANÜ says cancellation can be requested at info@manutelehealth.com and normally takes effect at the current billing cycle’s end unless otherwise specified. Partial billing periods are not refunded except where applicable law requires it. The general rule is that sales are final, with stated exceptions, and refunds generally are unavailable after services have been rendered or medications dispensed. Cancelling future renewal therefore should not be read as reversing an already completed charge.

If MANÜ cancels an order after payment, its terms promise a full refund to the original payment method. No bank-arrival timeline is established here. A different provision requires contacting the company at least 48 hours before a nutrition-store subscription renews; late requests may not prevent that cycle’s charge and shipment. That provision controls nutrition-store transactions where it conflicts with general terms. It should not automatically be imposed on the clinical subscription or mistaken for its cancellation deadline.

The privacy policy also describes access to an electronic or paper copy of health information, usually within 30 days, with a possible reasonable, cost-based fee. That offers a documented records pathway distinct from subscription cancellation. Before enrolling, retain the applicable checkout terms, receipt, assigned practice and pharmacy details, and cancellation instructions. These records help distinguish the clinical relationship, medication fulfillment and payment arrangement—three connected processes that MANÜ’s public documentation does not always describe with consistent specificity.

Sources: [13] [12]

Questions & answers

Does MANÜ offer FDA-approved semaglutide or tirzepatide?

The reviewed product pages advertise compounded injectable semaglutide and tirzepatide, not named FDA-approved branded products. Compounded preparations are not FDA approved. That status alone does not prove clinical inequivalence, but published trials cannot be treated as direct validation of MANÜ’s preparations. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug.

Sources: [6] [8] [1]

Can someone outside Florida use MANÜ?

The consulted documents do not resolve that question. The homepage advertises all-50-state coverage subject to address confirmation, but the privacy policy restricts access to Florida residents. Someone outside Florida should obtain a written explanation of current state availability and the applicable policy rather than assume the broader advertisement overrides the restriction.

Sources: [9] [12]

What would my first GLP-1 payment be?

The public documentation does not establish a complete first payment. The homepage shows both from $4/day and from $5/day without reconciling them or identifying the associated supply and billing terms. It says packages include consultation, medication, supplies and shipping. Request an itemized checkout quote and renewal schedule; the free initial assessment does not establish free treatment.

Sources: [9] [5]

Will a physician necessarily review my application?

A treatment page describes prescribing by a board-certified physician if approved, while the team page presents nurse practitioners and the terms refer more broadly to independent licensed healthcare professionals. The documents do not identify your assigned professional. Ask who reviews the application and prescribes, using the professional’s full name and credential rather than assuming every clinician is a physician.

Sources: [6] [7] [13]

Does MANÜ’s 24/7 support mean immediate medical advice?

No immediate response is established. MANÜ advertises 24/7 patient support, but its legal center warns that messages and refill requests may not be reviewed immediately. Ask about clinical escalation and response expectations. The platform is not an emergency service, and a support channel should not be treated as a substitute for emergency care.

Sources: [7] [10]

Must I cancel a clinical subscription 48 hours before renewal?

The documented 48-hour minimum notice belongs to nutrition-store subscriptions, not automatically to general clinical subscriptions. General cancellation is requested by email and normally takes effect at the current cycle’s end, with no partial-period refund unless legally required. Confirm your purchase-specific terms and keep the request and acknowledgment; cancellation itself does not establish a refund entitlement.

Sources: [13]

Our assessment

MANÜ documents a genuine advertised GLP-1 service: compounded injectable options, prescription-dependent access, pharmacy fulfillment, package inclusions and ongoing-support claims. Its acknowledgment that compounded products are not FDA approved is important. However, the public record does not substantiate MANÜ-specific treatment outcomes, and clinical trials cannot fill that gap. More immediately, inconsistent geographic restrictions and clinical-role descriptions make the enrollment decision harder than it should be. Complete cycle pricing, the assigned professional, the dispensing pharmacy and an operational follow-up plan remain essential confirmations. The balanced conclusion is neither that the service is proven ineffective nor that familiar medication names validate it. Its offering is identifiable, but several consequential responsibilities and transaction terms need clearer documentation before payment.

Visit MANÜ Telehealth’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

MANÜ Telehealth Review: What Its GLP-1 Documentation Establishes—and What It Does Not

At a glance

01Start with what the offering actually is

02The clinical research is not a MANÜ performance report

03Who is responsible for the clinical service?

04Access depends on more than completing the questionnaire

05Pharmacy fulfillment is documented more clearly than delivery timing

06Daily advertising prices do not establish the actual bill

07Follow-up claims need an operational explanation

08Cancellation and records have separate rules